CEA-based vaccines

References

• Gold P, Freedman SO. Demonstration of tumor-specific antigens in human colon carcinoma by immunologic tolerance and absorption techniques. I Exp. Merl 121, 439–486 (1965).
   PubMed Web of Science ®Google Scholar
• Von Kleist S, Burtin P Localisation cellulaire d'un antigen embryonnaire de tumeurs coliques humains. Int J. Cancer 4, 467–481 (1969).
   Google Scholar
• Hodge JW. Carcinoembryonic antigen as a target for cancer vaccines. Cancer Iminuttol. Immunother: 43,127–134 (1996).
   Google Scholar
• Beatty JD, Romero C, Brown PW et al. Clinical value of carcinoembryonic antigen. Diagnosis, prognosis and follow-up of patients with cancer. Arch. Surg. 114,563–567 (1979).
   Google Scholar
• Hayes DE Tumor markers for breast cancer. Hematology/Oncology Clinics of North America 8(3), 485–506 (1994).
   Google Scholar
• Vincent RG, Chu TM. Carcinoembryonic antigen in patients with carcinoma of the lung. I Thorac. Catrliovasc. Sing 66, 320–328 (1973).
   Google Scholar
• Goslin RII, Skarin AT, Zamcheck N. Carcinoembronic antigen: A useful monitor of therapy of small cell lung cancer. JAMA 246,2173–2176 (1986).
   Google Scholar
• Bates SE, Longo DL. Use of serum markers in cancer diagnosis and management. Semin. Stag °rico]. 14,102–138 (1987).
   Google Scholar
• Cooper MJ, Mackei CR, Skinner DB, Moosa AR. A reappraisal of the value of carcinoembryonic antigen in the management of patients with various neoplasms. Br. Silly 66,120–123, (1979).
   Google Scholar
• Hall RP, Laurence DJ, Carcy D et al Carcinoembryonic antigen in the urine of patients with urothelial carcinoma. BE Merl 3,609–611,1972.
   Google Scholar
• Ona SW Zamcheck N, Blair P et al. CEA in the dianosis of pancreatic cancer. Cancer 31,324–327 (1973).
   PubMed Web of Science ®Google Scholar
• Shimizu N, Walcatsuki T, Murakami A et al Carcinoembryonic antigen in gastric cancer patients. Oncology44, 240–244 (1987).
   Google Scholar
• Alexander JC, Chretien PB, Dellon AL, Snyder J. CEA levels in patients with carcinoma of the esophagus. Cancer42, 1492–1497 (1978).
   PubMed Web of Science ®Google Scholar
• Maxwell P Carcinoembryonic antigen: cell adhesion molecule and useful diagnostic marker. Br. Domed. Sci. 56,209–214 (1999).
   Google Scholar
• Thompson JA. Molecular cloning and expression of CEA gene family members. Tum. Bio115, 10–16 (1995).
   Google Scholar
• Wanebo JH, Rao G, Pinsky CM, et al Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N. Engl. J. Merl 299,448–451 (1978).
   PubMed Web of Science ®Google Scholar
• Bruinvels DJ, Stiggelbout AM, Kievit J, van Houlwelingen HC, Habbema JD, van der Velde CJ. Follow-up of patients with colorectal cancer: A meta-analysis. Ann. Surg: 219,174-182 (1994).
   Google Scholar
• Moertel CG, Fleming TR, Macdonald JS, Haier DG, Laurie JA, Tangen C. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JA/V/A 270(8), 943–947 (1993).
   Google Scholar
• Wang JY, Tang R, Chiang JM. Value of carcinoembryonic antigen in the management of colorectal cancer. Dis. Colon Rectum 37,272–277 (1994).
   PubMed Web of Science ®Google Scholar
• Huang A, Hindle KS, Tsavellas G. Colorectal surveillance post-surgery. Hosp. Med. 62(8), 490–491 (2001).
   Google Scholar
• Martinez DA, Barbera-Guillem E, LaValle GJ, Martin EW. Radioimmunoguided surgery for gastrointestinal malignancies: an analysis of 14 years of clinical experience. Cancer Control 4(6), 505–516 (1997).
   Google Scholar
• Tsang KW Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J. Generation of human cytotoxic T-cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccina-CEA vaccine. j Nat! Cancer Inst. 87(13), 982–990 (1995).
   Google Scholar
• Tanaka H, Tsunoda T, Nukaya I et al Mapping the HLA-A24-restricted T-cell epitope peptide from a tumour-associated antigen HER2/neu: possible immunotherapy for colorectal carcinomas. Br. Cancer84(1), 94–99 (2001).
   Google Scholar
• Reynolds SR, Cells E, Sette A et al Identification of HLA-A*03, A*11 and B*07-restricted melanoma-associated peptides that are immunogenic in vivo by vaccine-induced immune response (VIIIR) analysis. I Irnmun. 114thods 244(1), 59–67 (2000).
   Google Scholar
• Bakker AB, Schreurs MW, Tafazzul G et al. Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted antimelanoma CTL line. Int.j Cancer 62 (1), 97–102 (1995).
   Google Scholar
• Pogue RR, Eron J, Frelinger JA, Matsui M. Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitm imuunogenicity. Proc Natl Acad. Sc]. USA 92(18), 8166–8170 (1995).
   Google Scholar
• Lipford GB, Bauer S, Wagner H, Heeg K. Peptide engineering allows cytotoxic T-cell vaccination against human papilloma virus tumour antigen, E6. Immunology 84 (2), 298–303 (1995).
   Google Scholar
• Zaremba S, Barzaga E, Zhu M, Scares N, Tsang K, Schlom J. Identification of an enhancer agonist cytotoxic T-lymphocyte peptide form human carcinoembryonic antigen. Cancer Res 57,4570–4577 (1997).
   PubMed Web of Science ®Google Scholar
• Salazar E, Zaremba S, Arlen PM, Tsang KY, Schlom J. Agonist peptide from a cytotoxic T-lymphocyte epitope of human carcinoembryonic antigen stimulates production of Tcl -type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide. Int. Cancer 85,829–838 (2000).
   Google Scholar
• Fong L, Hou Y, Rivas A et al Altered peptide ligand vaccination with F1t3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl Acad. Sc]. USA 98(15), 8809–8814 (2001).
   Google Scholar
• Shu SY, Rosenberg SA. Adoptive immunotherapy of newly induced murine sarcomas. Cancer Res. 45(4), 1657–1662.
   Google Scholar
• Elias EG, Suter CM, Fabian DS. Adjuvant immunotherapy in melanoma with irradiated autologous tumor cells and low dose cyclophosphamide. I Surg. Oncol 64(1), 17–22 (1997).
   Google Scholar
• Du Bois JS, Trehu EG, Mier JW et al Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma. j Clin. Oncal 15(3), 1052–1062 (1997).
   Google Scholar
• Dranoff G, Jaffee E, Lazenby A et al Vaccination with irradiated tumor cells engineered to secrete murine granulocye-macrophage colony-stimulating factor stimulates potent, specific and long-lasting antitumor immunity. Proc. Natl Acad. Sc]. USA 90(8), 3539–3543 (1993).
   Google Scholar
• Simons JW. Bioactivity of human GM-CSF gene therapy in metastatic renal cell carcinoma and prostate cancer. Hnyokika I6yo 43(11), 821–822 (1997).
   Google Scholar
• Jaffee EM, Hruban RII, Biedrzycki B et al Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a Phase I trial of safety and immune activation. j Clin. Oncal 19(1), 145–156 (2001).
   PubMed Web of Science ®Google Scholar
• Arlen P, Tsang KY, Marshall JL et al The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines. Cancer Immunal Immunother. 49(10), 517–529 (2000).
   PubMed Web of Science ®Google Scholar
• Slingluff CL Jr, Yamshchikov G, Neese P et aehase I trial of a melanoma vaccine with gp100(280–288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin. Cancer Res. 7(10), 3012–3024 (2001).
   Google Scholar
• Pertmer TM, Eisenbraun MD, McCabe D, Prayaga SK, Fuller DH, Haynes JR. Gene gun-based nucleic acid immunization: elicitation of humoral and cytotoxic T-lymphocyte responses following epidermal delivery of nanogram quantities of DNA. Vaccine 13(15), 1427–1430 (1995).
   PubMedGoogle Scholar
• Conry RM, LoBuglio AF, Loechel F et al. A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity. Gene Therapy 2,59–65 (1995).
   PubMed Web of Science ®Google Scholar
• Wolff JA, Ludtke JJ, Acsadi G, Williams P, Jani A. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum. Mal Genet. 1(6), 363–369 (1992).
   Google Scholar
• Daro E, Butz E, Smith J, Teepe M, Maliszewski CR, McKenna HJ. Comparison of the functional properties of murine dendritic cells generated in vivo with flt3 ligand, GM-CSF and flt3 ligand plus gm-csf. Cytokine 17 (3), 119–130 (2002).
   Google Scholar
• Hiasa Y, Akbar SM, Abe M, Michitaka K, Horiike N, Onji M. Dendritic cell subtypes in autoimmune liver diseases; decreased expression of HLA DR and CD 123 on Type 2 dendritic cells. Hepatol Res. 22(4), 241–249 (2002).
   Google Scholar
• Lu L, Thomson AW. Manipulation of dendritic cells for tolerance induction in transplantation and autoimmune disease. 7iansplantation 73(1 Suppl.), S19-22 (2002).
   Google Scholar
• Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4(3), 269–270 (1998).
   Google Scholar
• Rains N, Cannan RJ, Chen W, Stubbs RS. Development of a dendritic cell (DC)-based vaccine for patients with advanced colorectal cancer. Hepato-gastroenterology 48,347–351 (2001).
   PubMed Web of Science ®Google Scholar
• Kugler A, Stuhler G, Walden P et al Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat. Med. 6(3), 252–253 (2000).
   Google Scholar
• Kantor J, Irvine K, Abrams S, Kaufman H, DiPietro J, Schlom J. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J. Nat! Cancer Inst. 84(14) (1992).
   Google Scholar
• Zhu M, Marshall J, Cole D, Schlom, Tsang KY. Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine. Clin. Cancer Res. 6,24–33 (2000).
   Google Scholar
• Hammond AL, Plemper RK, Zhang J, Schneider U, Russell SJ, Cattaneo R. Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen. J. Virol 75(5), 2087–2096 (2001).
   PubMed Web of Science ®Google Scholar
• Xiang R, Silletti S, Lode HN et al Protective immunity against human carcinoembryonic antigen (CEA) induced by an oral DNA vaccine in CEA-transgenic mice. Clin. Cancer Res. 7,856s-864s (2001).
   Google Scholar
• Xiang R, Primus FJ, Ruehlmann JM et al A dual-function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T-cell-mediated protective Immunity against colon cancer in carcinoembryonic antigen-transgenic mice. Immune/. 167(8), 4560–4565 (2001).
   Google Scholar
• Clay TM, Hobeika AC, Mosca PJ, Lyerly HK, Morse MA. Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clin. Cancer Res. 7,1127–1135 (2001).
   PubMed Web of Science ®Google Scholar
• Honig H, Lee DS, Conkright W et al Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 costimulatory molecule. Cancer Immunol Immunother. 49,504-514 (2000).
   Google Scholar
• von Mehren M, Arlen P, Gulley J et al The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastaticcarcinoma. Clin. Cancer Res. 7(5), 1181–1181 (2001).
   Google Scholar
• Hobeika AC, Clay TM, Mosca PJ, Lyerly HK, Morse MA. Quantitating therapeutically relevant T-cell responses to cancer vaccines. Crit. Rev Immunol . 21(1–3), 287–297 (2001).
   Google Scholar
• Giuletti A, Overbergh L, Valckx D, Decallonne B, Bouillon R, Mathieu C. An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Method 25(4), 386–401 (2001).
   Google Scholar
• Freeman WM, Walker SJ, Vrana KE. Quantitative RT-PCR: pitfalls and potential. Biotechniques 26(1), 112–122 (1999).
   PubMed Web of Science ®Google Scholar
• Kim CJ, Reintgen DS, Yeatman TJ. The promise of microarray technology in melanoma care. Cancer Contm19(1), 49–53 (2002).
   Google Scholar
• Granucci F, Castagnoli PR, Rogge L, Sinigaglia F. Gene expression profiling in immune cells using microarray. Int. Arch. Immunol 126(4), 257–266 (2001).
   Google Scholar
• Armstrong AC, Hawkins RE. Vaccines in oncology: background and clinical potential. BE J. Radio!. 74,991–1002 (2001).
   Google Scholar
• Schwartzentruber DJ. Guidelines for the safe adminstration of high-dose interleukin-2. j Immunother. 24(4), 287–293 (2001).
   Google Scholar
• Rosenberg SA, Yang JC, Schwartzentruber DJ et al Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4(3), 321–327 (1998).
   PubMed Web of Science ®Google Scholar
• Marshall JL, Hoyer RJ, Toomey MA et al Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anticarcinoembryonic antigen immune responses. j Clin. Oncol 18(23), 3964–3973 (2000).
   Google Scholar
• Bronte V, Thung K, Rao JB et al IL-2 enhances the function of recombinant xvirus-based vaccines in the treatment of established pulmonary metastases. J. Immunol 154(10), 5282–5292 (1995).
   Google Scholar
• Trinchieri G. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv. Immunol 70,83–243 (1998).
   Google Scholar
• Robertson MJ, Cameron C, Atkins MB et al Immunological effects of interleukin-12 administered by bolus iv. injection to patients with cancer. Clin. Cancer Res. 5,9-16(1999).
   Google Scholar
• Rao JB, Chamberlain RS, Bronte V et al IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. J. Immunol 156(9), 3357–3365 (1996).
   Google Scholar
• Schmitt M, Ikeda H, Nagata Y etal Involvement of T-cell subsets and natural killer (NK) cells in the growth suppression of murine fibrosarcoma cells transfected with interleukin-12 (IL-12) genes. Int Cancer72(3), 505–511 (1997).
   Google Scholar
• Kaufman HL, Flanagan K, Lee CS, Perretta DJ, Honig H. Insertion of interleukin-2 (IL-2) and ilterleukin-12 (IL-12) genes into vaccinia virus results in effective antitumor responses without toxicity. Vaccine 20(13), 1862–1869 (2002).
   Google Scholar
• McLaughlin JP, Abrams S, Kantor J et al Immunization with a syngeneic tumor infected with recombinant vaccinia virus expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) induces tumor regression and long-lasting systemic immunity. I Immunother. 20(6), 449–459 (1997).
   Google Scholar
• Nishisaka N, Maini A, Kinoshita Y etal Immunotherapy for lung metastases of murine renal cell carcinoma: synergy between radiation and cytokine-producing tumor vaccines. J. Immunother. 22(4), 308–314 (1999).
   Google Scholar
• Bretscher P. The two-signal model of lymphocyte activation twenty-one years later. Immunol Today13(2), 74–76 (1992).
   Google Scholar
• Bluestone JA. New perspectives of CD28- B7-mediated T-cell costimulation. Immunity2,555 (1995).
   PubMed Web of Science ®Google Scholar
• Miller SD, Vanderlugt CL, Lenschow DJ et al. Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE. Immunity3, 739 (1995).
   PubMed Web of Science ®Google Scholar
• Yu X, Abe R, Hodes R. The role of B7- CD28 costimulation in tumor rejection. kit Immunology10,791 (1998).
   Google Scholar
• Eck SC, Turka LA. Generation of protective immunity against an immunogenic carcinoma requires CD40/ CD4OL and B7/CD28 interactions but not CD4(+) T-cells. Cancer Immunol Immunother. 48(6), 336–341 (1999).
   Google Scholar
• Hodge JW, McLaughlin JP, Abrams SI, Shupert WL, Schlom J, Kantor JA. Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity. Cancer Res. 55(16), 3598–3603 (1995).
   Google Scholar
• von Mehren M, Arlen P, Tsang KY et al Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin. Cancer Res. 6, 2219–2228 (2000).
   Google Scholar
• Kwon ED, Foster BA, Hurwitz AA et al Elimination of residual meatstatic prostate cancer after surgery and adjunctive cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Pmc. Natl Acad. Sci. USA 96(26), 15074–15079 (1999).
   Google Scholar
• Frauwirth IKA, Thompson CB. Activation and inhibition of lymphocytes by costimulation. j Clin. Invest. 109(3), 295–299 (2002).
   Google Scholar
• Shankar P, Schlom J, Hodge JW. Enhanced activation of rhesus T-cells by vectors encoding a triad of costimulatory molecules as(B8L-1, ICAM-1, LFA-3). Vaccine 20(5–6), 744–755 (2001).
   Google Scholar
• Fujii H, Inobe M, Kimura F et al Vaccination of tumor cells transfected with the B7-1 (CD80) gene induces the antimetastatic effect and tumor immunity in mice. Intj Cancer 66(2), 219–224 (1996).
   Google Scholar
• Irvine KR, Chamberlain RS, Shulman EP, Surman DR, Rosenberg SA, Restifo NP Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J. Nat! Cancer Inst. 89(21), 1595–1601 (1997).
   Google Scholar
• Andrew ME, Coupar BE, Boyle DB. Humoral and cell-mediated immune responses to recombinant vaccinia viruses in mice. Immund Cell Biol. 67(5), 331–337 (1989).
   Google Scholar
• Bruno L, Kirberg J, von Boehmer H. On the cellular basis of immunological T-cell memory. Immunity2(1), 37–43 (1995).
   Google Scholar
• Kundig TM, Bachman ME, Oehen S et al. On the role of antigen in maintaining cytotoxic T-cell memory. Pmc. Natl Acad. Sc]. USA 93(18), 9716–9723 (1996).
   Google Scholar
• Modlin JF, Halsay NA, Thoms ML, Meschievitz CK, Patriarca PA. Humoral and mucosal immunity in infants induced by three sequential inactivated poloiovirus vaccine-live attenuated oral poliovirus vaccine immunization schedules. Baltimore Area Polio Vaccine Study Group. J. Infect. Dis. 175\(Suppl. 1), S228-234 (1997).
   Google Scholar
• Zannoli R, Morgese G. Hepatitis B vaccine: current issues. Ann. Pharmacother. 31(0, 1059–1067 (1997).
   Google Scholar
• Marshall JL, Hawkins MJ, Tsang KY et al. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. j Clin. Oncol. 1,332 (1999).
   Google Scholar
• Clarke P, Mann J, Simpson JF, Rickard- Dickson K, Primus FJ. Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy. Cancer Res. 58(7), 1469–1477,1998.
   PubMed Web of Science ®Google Scholar
• Honig H, Wainstein A, Long L et al A new mouse model for evaluating the immunotherapy of human colorectal cancer. Cancer Res. 61(23), 8520–8526, 2001.
   Google Scholar